Consistent with this, IFNγ signaling was associated with NK cell ... E can protect circulating tumor cells from NK cell lysis via NKG2A, suggesting that targeting the NKG2A axis could be a ...

The team determined that a key checkpoint in the immune system—called NKG2A—doesn't engage with its specific binding molecule expressed in cancer cells until the appropriate signal is received.

Figure 1: Cancer therapeutics targeting the NKG2A:HLA-E axis. The NKG2A:HLA-E interaction can be inhibited by antibodies targeting either NKG2A (monalizumab, BMS-986315) or HLA-E (3H4, TFL-033).

Researchers from Elpiscience Biopharmaceuticals Inc. discussed the discovery and preclinical characterization of a novel NKG2A antibody-IL-2 mutant fusion protein – ES-015.129 – being developed as ...

Moreover, other inhibitory receptors like CD94/NKG2A, PD-1, TIGIT ... CIS, a negative regulator of IL-15 signaling, is upregulated by IL-15 in NK cells, and its absence enhances NK cell ...

Moreover, other inhibitory receptors like CD94/NKG2A, PD-1, TIGIT ... CIS, a negative regulator of IL-15 signaling, is upregulated by IL-15 in NK cells, and its absence enhances NK cell ...

The INTERLINK-1 trial was testing monalizumab – an NKG2A receptor inhibitor – in combination with EGFR-targeting antibody cetuximab in patients with recurrent or metastatic squamous cell ...